Jetrea Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of surgical vitrectomy, rising prevalence of age related eye disorders, early clinical validation of ocriplasmin, increasing ophthalmologist awareness, demand for non surgical retinal interventions.

The growth in the forecast period can be attributed to aging global population, growth in retinal specialty clinics, increased screening for macular conditions, preference for office based treatments, continued innovation in ophthalmic enzymes. Major trends in the forecast period include increasing adoption of pharmacologic vitreolysis, rising preference for minimally invasive retinal treatments, growing diagnosis of vitreomacular disorders, shift toward enzyme based ophthalmic therapies, expansion of outpatient retinal care.

The increasing prevalence of retinal diseases is expected to drive the growth of the Jetrea market in the coming years. Retinal diseases refer to a range of conditions that affect the retina, the light-sensitive tissue at the back of the eye, and can potentially lead to vision loss or blindness if left untreated. The rise in retinal diseases is primarily due to aging populations, higher rates of diabetes, and increased exposure to risk factors such as hypertension and lifestyle changes. Jetrea (ocriplasmin) is used to treat vitreomacular traction and macular holes, helping address specific retinal diseases related to age-related and diabetic eye conditions. For example, in May 2024, The Royal College of Ophthalmologists, a UK-based public college, projected that the prevalence of sight loss and blindness caused by age-related macular degeneration (AMD) will rise to 29.7% by 2050, up from 23.1% in 2024. This would increase the affected population from approximately 445,809 individuals to an estimated 1.23 million. Therefore, the increasing prevalence of retinal diseases is a significant driver for the Jetrea market.

The increasing number of clinical trials is expected to drive the growth of the Jetrea market in the coming years. Clinical trials are structured research studies designed to evaluate the effectiveness, safety, and potential side effects of medical treatments, drugs, or devices in humans. The rise in clinical trials reflects the growing complexity of healthcare needs, advancements in scientific research, and the broader scope of medical investigations. Jetrea, with its innovative mechanism for treating symptomatic vitreomacular adhesion (sVMA), contributes to clinical trials by providing a targeted therapeutic option that enhances the evaluation of efficacy and safety in resolving this condition, thereby advancing research in retinal health. For example, in October 2024, ClinicalTrials.gov, a US-based government clinical trials registry, reported that in 2023, a total of 39,710 new studies were registered, bringing the cumulative total to 477,203 studies by the end of the year. This compares to 38,023 new studies registered in 2022, which brought the cumulative total to 437,493 studies by the end of 2022. Therefore, the rising number of clinical trials is playing a significant role in driving the growth of the Jetrea market.

The growing demand for personalized medicine is also expected to propel the growth of the Jetrea market. Personalized medicine is an approach that tailors treatment and healthcare strategies to an individual’s unique characteristics, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rise in personalized medicine is driven by advancements in genomic technologies, better understanding of molecular biology, increased availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Personalized medicine benefits from Jetrea’s precise mechanism of action, which targets specific retinal conditions, such as symptomatic vitreomacular adhesion (sVMA), offering a non-surgical, tailored treatment option that meets the unique needs of individual patients. For example, as of early 2025, the Drug Information Association (DIA) Global Forum reported that the FDA has approved over 30 cell and gene therapies, with industry experts forecasting an additional 30-50 approvals by 2030. Therefore, the rising trend of personalized medicine is contributing to the growth of the Jetrea market.

Major companies operating in the jetrea market are Oxurion NV (Formerly ThromboGenics Inc.)

North America was the largest region in the Jetrea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the jetrea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the jetrea market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the jetrea market by increasing costs related to importing biologic enzyme inputs, sterile ophthalmic packaging, and cold chain distribution materials. These impacts are more evident in hospital and specialty eye clinic segments across import dependent regions such as asia pacific and europe. Higher supply chain costs can affect pricing and treatment accessibility. At the same time, tariffs are encouraging regional manufacturing partnerships and localized supply strategies for ophthalmic biologics.

The jetrea market research report is one of a series of new reports that provides jetrea market statistics, including jetrea industry global market size, regional shares, competitors with a jetrea market share, detailed jetrea market segments, market trends and opportunities, and any further data you may need to thrive in the jetrea industry. This jetrea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Jetrea (ocriplasmin) is a pharmacologic agent used to treat vitreomacular adhesion (VMA) and macular hole. It works by enzymatically breaking down the proteins responsible for the abnormal adhesion between the vitreous body and the macula, a condition that can lead to visual impairment.

The primary indications in the Jetrea market include vitreomacular traction (VMT), symptomatic vitreomacular adhesion, and combination therapy. Vitreomacular traction (VMT) occurs when the vitreous gel, which fills the eye, adheres abnormally to the macula, the central part of the retina responsible for sharp, detailed vision. The patient demographics for Jetrea include adult patients, elderly individuals, and high-risk groups. Distribution channels for Jetrea include direct sales, pharmaceutical wholesalers, online pharmacies, and international markets. The key end users of Jetrea include ophthalmologists, hospitals and clinics, outpatient surgical centers, and research institutions.

The jetrea market consists of sales of jetrea as single use intravitreal injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.